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Increasing the Clinical Efficacy of Radiotherapeutics for Solid Tumors by Inhibition of
Hypoxia Inducible Factor-1a
Abstract: Radiotherapy is commonly used in a variety of tumor types and is effective in control of long term
progression and may be curative under certain circumstances. Radiotherapeutics have been shown to be the single
most effective therapeutic for cancer and only account for 5% of the total cost. However, treatment of cells with
radiation causes the tumor microenvironment to undergo changes and leads to cycles of hypoxia inside the tumor
which allows for the cell to undergo angiogenesis, metastasize and may lead to repopulation of the tumor. Current
systemic chemotherapeutics typically have an additive toxicity due to the unintended targeting of non-cancerous
cells. A nanoparticle conjugated with the iRGD peptide is proposed to allow for selective uptake by the CendR
pathway in the tumor tissues. A systemic selective chemotherapeutic agent that will inhibit hypoxia inducible factor1, preventing angiogenesis, that is co-administered with radiotherapy may increase the clinical efficacy of the
radiotherapeutics and may have the greatest impact on currently available cancer treatment.

Introduction
Radiotherapy (RT) is used as a
treatment option for approximately 50% of all
cancer patients. RT has shown to be effective
in the control of the long-term progression of
tumors and in a substantial proportion of cases
can be curative (1). According to the National
Cancer Institute, there are two main forms of
radiotherapy, internal radiation therapy and
external beam radiation. Internal radiation
therapy requires the source of radiation to be
put within one’s body. The form of radiation
can either be solid or liquid. Internal radiation
therapy with a solid source is termed
brachytherapy and is a form of local
treatment, meaning it treats only a specific
part of your body. Internal radiation with a
liquid source is called systemic therapy. This
form of radiation will be transported in the
blood to tissues throughout the body, where it
will target and kill cancer cells. External beam
radiation therapy is a form of local treatment
that is accomplished by focusing a beam of
radiation on the tumor (2).

Radiotherapy has been shown to activate
a connected series of processes in tumor
microenvironments including: inflammation,
cycling hypoxia, revascularization and
extracellular matrix remodeling (ECM) (3).
Radiotherapy can cause cell death by inducing
DNA damage. The induction of DNA damage
is caused directly or indirectly by free radicals
which are generated from the radiolysis of
water. In the presence of oxygen, O2,
generation of reactive oxygen species occurs
and acts as a positive feedback loop, further
enhancing DNA damage (4).
Combining RT with a systemic
treatment option, either with a biologically
targeted chemotherapeutic or a cytotoxic
chemotherapeutic to further enhance RT has
had extensive interest in clinical research. A
combinational therapy option would be
beneficial over a prolonged course of RT due
to the time it takes for DNA damage to cause
cell death (5). One example of a current
combination therapy option is the use of
Cisplatin with RT which has shown to be
beneficial for: head and neck, lung,
esophageal, cervical, and bladder cancers (6).
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This form of combinational therapy has
shown to increase the clinical efficacy of RT,
compared to if RT or cisplatin were used alone
(7). However, Cisplatin has the ability to
arrest cells in the G2 phase of the cell cycle,
and when it targets noncancerous tissues, it
leads to an additive toxicity (7).
Due to this fact, research into systemic
chemotherapeutics that will not lead to
additive toxicity is necessary. In this
literature review, the idea of using a
nanoparticle that will induce inhibition of
HIF-1a as a form of a biologically targeted
systemic chemo-therapeutic agent along with
RT to increase the clinical efficacy of RT is
looked at as a possible new therapeutic
approach.
The tumor microenvironment
Solid tumors are not only composed
of malignant cancerous cells but also include
a collection of stromal cells that are related
to: angiogenesis, inflammation, and growth
of fibrous or connective tissue (8). This
creates an atypical ECM that harbors cells
including: fibroblasts, immune cells, red
blood cells, epithelial cells, and endothelial
cells. The cancerous cells take advantage of
the densely packed ECM via mutations to
create a harsher environment that supports
tumor progression and treatment
resistance.(9) This environment is thought to
arise during the rapid proliferation of the
cancerous cells. During this state of tumor
development, the cells use vast amounts of
nutrients and oxygen from normal
vasculature which quickly leads to a hypoxic
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state, an oxygen deprived state, and a nutrient
deprived state inside the solid tumor (10).
The hypoxic state leads to the
activation of the hypoxic pathway through the
activation of the hypoxia inducible factor 1
(HIF-1). HIF-1 is a heterodimeric protein
consisting of 2 subunits, HIF-1a and HIF-1b.
Both subunits are composed of basic helixloop-helix proteins, and when combined act as
a transcription activator for the subset of HIF1 targeted genes (10). HIF-1b is a member of
the Aryl hydrocarbon nuclear translocator
family, and is only found in the nucleus (11).
Meanwhile, HIF-1a under normal oxygen
conditions is found in the cytosol and
undergoes rapid degradation (9).
HIF-a degradation is associated with
the enzyme proline hydroxylase. Under
normal oxygen conditions, HIF-a is
transcribed and translated at a high rate but
almost immediately undergoes degradation.
Proline hydroxylase is responsible for the
oxidation of 1 or 2 proline residues of HIF-1a
to hydroxyproline. After conversion to
hydroxyproline, pVHL will bind to HIF-1a,
and catalyze the addition of numerous
ubiquitin molecules to the protein. Ubiquitin
acts as a biological tag, and will signal for
HIF-1a to be degraded in a proteasome (9).
In oxygen deprived conditions,
proline hydroxylase fails to oxidize the
proline residues. This allows for HIF-1a to
evade degradation, allowing for the protein to
translocate to the nucleus where it binds with
HIF-1b and forms the heterodimeric protein
leading to its activation (1). In previous
studies, it has been found there are three
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variants to the HIF heterodimeric protein
which contain variant a subunits. These
variants are termed as HIF-1a, HIF-2a and
HIF-3a (12). HIF-1a and 2a have been
shown to act similarly except in rare
occasions of overexpression of the asubunits in different cancer subtypes. HIF-3a
has actually been shown to inhibit HIF-1a
and HIF-2a (12). In this article, the focus is
on the variant HIF-1a and how it leads to
changes in the tumor microenvironment
during hypoxic states inside solid tumors.
Disarrayed vasculature
Cytokine signaling for activation of
endothelial cells during cycles of hypoxia
inside solid tumors is known to cause
formation of new vasculature by a process
called angiogenesis (13). A hallmark
regulator of angiogenesis is the hypoxic
pathway. Upon formation of the
heterodimeric transcription factor HIF-1,
gene transcription for over 200 genes
becomes induced. Of these 200 genes, which
mostly are poorly understood, there are three
main pro-angiogenic factor genes known to
induce angiogenesis: Vascular endothelial
growth factor (VEGF), platelet-derived
growth factor (PDGF), and transforming
growth factor-a (TGF-a) (9). VEGF will
induce the recruitment and maturation of
endothelial cells to form new capillaries
within the solid tumor (14). PDGF stimulates
mesenchymal cells, such as fibroblasts and
pericytes which are associated with
endothelial cells and help in the formation of
new capillaries. TGF-a stimulates the
recruitment and maturation of many types of
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cells to the tumor ECM including epithelial
cells (9).
When forming new vasculature, first
there must be some degradation of the
existing ECM to create space for the
formation of the new vessels. Matrix
metalloproteinases (MMPs) are responsible
for this degradation. MMP-2 is known to be
directly expressed upon activation of HIF-1
(11). In the ECM, after degradation occurs,
newly recruited endothelial cells will migrate
to the area and form new endothelial tubes.
These endothelial tubes are the primary
structure of new capillary beds. Branching of
these tubes is known to arise during
modulation of Notch signaling. HIF-1a is
responsible for the modulation of the Notch
signaling by directly binding to the Notch
intracellular domain. Newly recruited
endothelial cells will begin forming tubes
that extend from existing vascular network
on the leading edge. After formation of these
newly formed tubes, the immature
endothelial cells will recruit vascular
supporting cells, which have already been
recruited to the tumor microenvironment by
PDGF. The supporting cells include pericytes
and smooth muscle cells that will form the
basement membrane around the endothelial
tube, leading to the formation of new
vasculature and capillary beds. The final step
in the formation of the vasculature is
accomplished by fibronectin. Expression of
fibronectin has been shown to be directly
regulated HIF-2a in hypoxic states (11).
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New vasculature formation is
disarrayed when compared to that of normal
tissue. Upon modulation of Notch signaling,
by HIF-1a, extensive branching occurs in the
newly formed vasculature. In normal tissue,
branching of the vasculature is under tight
regulation. Every cell needs to be within a
certain distance, approximately 40 microns
between adjacent capillaries, to ensure
adequate oxygen and nutrients are available
for the cells. Typically, in most living tissue
there is only 1 to 3 cells that span the width
of a capillary bed(15).
In solid tumors, it has been shown
that this branching is more extensive, due to
the rapid proliferation of the tumor cells.
Rapid proliferation means the tumor will
have a higher metabolic demand, which leads
to the production of excessive pro-angiogenic
factors. Also, tumor vessels are continuously
being remodeled inside solid tumors, leading
to endothelial cells losing contact with the
basement membrane, causing the capillary
beds to rupture. The rupturing of capillaries
causes the vessels to have larger pores and
become leaky (16).
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leakage of proteins and fluids occur. This
leads to an elevated microvascular pressure
(MVP) and a decreased osmotic pressure
compared to that of normal tissue. The fluid
buildup in the tumor is a result of the lack of
lymphatic vessels that normally uptake
excess fluid present in the interstitial fluid
(1). Due to these changes, there are
implications for the delivery and uptake of
nanoparticles into solid tumors.
Along with the buildup of fluid, the
cancerous cells are undergoing rapid
proliferation which leads to an increase in
STP. As STP increases, there is a direct
correlation with the collapse of vasculature.
This leads to an increase in vascular blood
flow resistance, resulting in a greater increase
of IFP and MVP promoting the accumulation
of more fluid in the interstitium of the tumor
(1). Depending on the location in the tumor,
IFP changes due to STP. In the center of the
tumor, there is the greatest density of cells,
leading to a high STP. This leads to a
uniform elevation of IFP that will approach
MVP. When IFP is near or equal to that of
MVP, there is a limited transport of
pharmaceuticals, oxygen and nutrients (1).

Tumor hypoxia effects
The network of vasculature that is
formed during cycles of hypoxia inside
tumors is known to cause an increase in
interstitial fluid pressure (IFP) and solid
tissue pressure (STP) due to the rupturing of
capillaries and the lack of formation of
lymphatic vessels inside solid tumors. In
most solid tumor animal models, IFP will
increase between 10-100 mmHg (17). Due to
the leakage the capillary beds, excessive

Near the edges of tumors, there is a
decrease in STP because there is a lower
density of cells. This means that there will be
a lower IFP on the edges of tumors, but
because it is higher than that of surrounding
tissue, there is a possible outflow of fluid
into surrounding tissue (1). This
representation of the solid tumor
microenvironment explains how the
insufficient fluid flow works in favor of the
tumor, allowing it to evade the immune
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system by preventing antigen presenting cells
from leaving the tumor and preventing the
uptake of chemotherapeutics into the core of
the tumor.

metastatic phenotypes (20). This implicates
the direct correlation of HIF-1a and
metastasis, showing that TWIST1 is
responsible for the EMT.

Individuals with solid tumors that
have cycles of hypoxia are known to have
poor prognoses (18). This is due to the
positive correlation in cycling hypoxia
leading to increased tumor aggressiveness
and resistance to radiotherapy and
chemotherapeutics (18). As shown
previously, cycling hypoxia within solid
tumors leads to the formation of new
vasculature, that presents implications for the
uptake of chemotherapeutics and certain
radiotherapeutics.

According to K.J. Wu, who created a
method for predicting metastatic potential in
head and neck squamous cell carcinomas
(HNSCCs) that co-express: HIF-1a,
TWIST1 and SNAIL1, there was more than a
90% probability of metastasis. Comparing
that to HNSCCs that co-express TWIST1 and
SNAIL1, not HIF-1a, only had a 50%
probability of metastasis (21). Based on his
predictions, HNSCCs that co-express all
three proteins have a substantially greater
probability of metastasis, leading to a poorer
prognosis and patient survival rate.

According to the National Cancer
Institute, tumor aggressiveness is defined by
the ability of a tumor to form, grow, or
spread quickly (19). For a tumor to spread,
metastasize, the tumor cells will undergo an
epithelial-to-mesenchymal transition (EMT).
For an EMT to occur, there are a variety of
transcription factors that need to be activated.
Two of these transcription factors are
TWIST1 and SNAIL1.
In a study conducted by Yang et al.,
it was shown that HIF-1a regulates the
expression of TWIST1 upon binding to the
hypoxia-response element (HRE) which is
found in the proximal promoter of TWIST1
(20). This means HIF-1a is directly
correlated to the ability of the tumor to
promote metastasis leading to a worse
prognosis. However, when they used siRNAmediated repression of TWIST1 in an
environment where HIF-1a was over
expressed, the cells reversed the EMT and

TWIST1 is unique because not only
does it help trigger an EMT, but it also has
been shown to facilitate tumor cells to escape
the senescence program found within every
eukaryotic cell (22). The senescence program
determines how many times a cell is allowed
to replicate before it become senescent, the
inability to proliferate, acting as a
generational clock. In a normal cell, this is
typically around 70 cell cycles. Upon
completion of each cell cycle, the telomeres
at the end of the DNA will be shortened (9).
This means tumor cells expressing TWIST1
have the ability to replicate with telomere
lengths that would normally trigger
apoptosis.
When cells are allowed to replicate
without a proper senescence program, there
is an increase in genomic instability. This
occurs due to chromosomal end-to-end
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fusions that are called breakage-fusionbridge (BFB) cycles. Telomeres normally
prevent this from occurring by capping the
ends of chromosomes. When chromosomes
become uncapped, such as in a cell without a
proper senescence program, BFBs cause the
fusion of sister chromatids and random
breaks, which may cause new mutations to
occur (23). The formation of new mutations
in the DNA of the cancerous cells may
increase tumor aggressiveness by inducing
changes that increase the ability of the
cancerous cell to proliferate, grow, or to
metastasize.
Effect of radiotherapy on the tumor
microenvironment
Radiation therapy is known to kill
cancer cells by directing high physical
energy in forms of radiation onto the cancer
cells. RT has been used as a cancer
therapeutic since the late 19th century.
Through years of research, numerous
advancements have been made in the clinical
efficacy of RT (2). As we gain a better
understanding of the molecular mechanisms
in treatment sensitivity and resistance, these
advancements have been made possible. RT
is most commonly used in the treatment of
localized malignant tumors during the
progression of cancer. Recent studies have
shown that radiotherapy is the single most
cost-effective cancer therapeutic and
accounts for only 5% of the total cost of
cancer care. Due to this fact, increasing the
clinical efficacy of RT would benefit the
largest number of patients (5).
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Tumor cell death
Radiotherapy directly causes tumor
cell death, resulting in the reduction of the
cell population by numerous mechanisms.
Ionizing radiation can act on the cancer cells
by causing direct damage to the cell
membranes leading to cell lysis (5). Also,
ionizing radiation can lead to the production
of free radicals which are produced by the
ionization or excitation of water within the
cells. These free radicals can cause direct
DNA damage, which will not cause direct
cell death, but if not repaired, will lead to
cancer cell death. The most lethal forms of
DNA damage will induce double stranded
breaks which will result in cell death if not
repaired adequately. However, if the cancer
cell is able to adequately repair the DNA
damage, the cell will be able to survive and
increase their genomic stability (5).
During the course of a multi-day
course of RT to a radio-responsive tumor, the
total mass of the tumor will be decreased,
leading to a decrease in the tumor’s
production of pro-angiogenic cytokines,
which causes the endothelial cells making up
the vasculature to destabilize, leading to the
regression of the vasculature (1). This will
ultimately lead to the tumor to have a
decrease in blood supply, lowering the
availability of nutrients and oxygen and will
trigger the portion of solid tumor that is still
intact to become hypoxic. Activation of the
hypoxic pathway has been well known to
occur following radiation treatments.

INCREASING THE EFFICACY OF RADIOTHERAPEUTICS

Effects of hypoxia pathway post-treatment
Angiogenesis has been shown to be
correlated with activation of the hypoxic
pathway. Upon completion of treatment with
RT, solid tumors have been shown to
experience hypoxia. After RT, it has been
shown that in solid tumors, the
proangiogenic cytokines increase
dramatically in the following 6-8 hours (18).
This means, if the patient is undergoing RT
every other day, by the beginning of the next
round of RT, the tumor will have already
undergone angiogenesis and may have
possibly repopulated due to the resupply of
nutrients and oxygen to the solid tumor.
Cancer stem cells (CSCs) are the main
reason for tumor regrow after the
completion of a course of RT.
CSCs are fully capable of repopulating a
tumor due to their ability to activate
telomerase, an enzyme that increases the
length of telomeres, giving the cells the
ability to replicate without a senescent
program. The majority of the cells that make
up the human body do not have this ability.
Thus, if CSC’s arise, they play a key role in
inhibiting an effective cancer treatment.
Recent studies have provided evidence that
suggests hypoxia promotes the persistence of
stem cells (24). In a study by Gianluca
D’Ippolito, mesenchymal cells were isolated
and cultured at various levels of oxygen. It
was found that under higher levels of
oxygen, differentiation was more likely to
occur. Also, when the PO2 was decreased,
mimicking a hypoxic environment, the stem
cells were more likely to not differentiate and
maintained their self-renewal capabilities
(25).
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CSCs have also been directly
correlated with a solid tumor’s ability to
undergo metastasis, a process that was
explained above to also be influenced by
hypoxia. Stated by Richard Hill, “The
potential role of hypoxia in enhancing EMT
and stemness in cells raises the possibility
that the adverse effects of tumor hypoxia
might be partially explained by its dual
effects of promoting EMT and the selfrenewal of CSCs” (24). Treatment resistant,
or commonly known as radio-resistant, cells
provide an obstacle during the course of RT
treatment. If radio-resistant cells are present
in the tumor, the RT will be ineffective at
clearing the totality of the tumor mass (1).
Nanoparticle based radio-chemotherapy
Nanotherapeutic specific for HIF-1a
inhibition
Currently, a surplus of HIF-1a
inhibitors have been created and designed.
However, these inhibitors have been shown
to have numerous downstream effects,
leading to the creation of adverse effects
when used as a systemic chemotherapeutic
agent (26). Lack of targeting HIF-1a on the
surface of cancerous cells has been an
important obstacle in the creation of a
systemic chemotherapeutic agent. Also, HIF1 has numerous downstream affects due to its
ability to upregulate numerous genes which
increases its risk of additive toxicity (10).
However, if we are able to specifically target
the inhibition of HIF-1a only in cancer cells,
there would be a decrease in adverse effects
and would result in a systemic
chemotherapeutic that would have an
increased efficacy(3).
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As described above, the vasculature in solid
tumors is unlike that of normal tissue. The
endothelial cells are more spaced out,
creating larger pores, leading to the
vasculature to be leakier. Due to this, it is
proposed to design of a nanoparticle that
would be larger than that of the pores of
normal vasculature, which is in the range of
6-12 nm (27).
Delivery of nanotherapeutics to solid tumors
is believed to be increased by administering
the nanoparticle systemically. By creating a
stable nanoparticle that has a long half-life,
the chances of it actually reaching the
vasculature and being transported into the
solid tumor without crossing the normal
vasculature wall will decrease adverse effects
(27). Renal clearance of particles that are
smaller than 6 nm is very rapid and clearance
of particles in the spleen of a nanoparticle
that is larger than 200nm will also increase
(27). Based on these findings, a particle in
the range of 12-200 nm would have an
increase in half-life, thereby increasing the
possibility that it would enter the solid tumor.
Nanoparticles that are currently in
clinical trials are typically found to have a
size within this range (27). The most
common type of nanoparticle that has been
tested in these clinical trials uses a liposomal
formulation, which can be designed to be a
specific size(28). By using a liposomal
formulation, the nanoparticle delivery is
believed to increase, and can be designed so
that upon uptake into the tumor
microenvironment, based on physiological
characteristics such as pH, targeted release of
the HIF-1a inhibitor could be achieved (28).
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Specific targeting and the synergist effects of
radio-chemotherapy
Specific targeting of solid tumors by
a chemotherapeutic through the CendR
pathway has been under extensive research.
The CendR pathway involves a three-step
process using a tumor targeting peptide
(TTP) sequence leading to the formation of
endocytic vesicles that are approximately
200nm (29). In the first step, an integrinbinding RGD (iRGD) sequence motif within
the TTP binds to avb3 and avb5 integrins
which are specifically expressed by tumor
endothelial cells. Upon binding, the sequence
is cleaved by an unknown protease leading to
the activation of a second motif in the
sequence, the CendR motif (R/KXXR/K).
The CendR motif can then bind to
neuropilin-1 and neuropilin-2, which
activates the CendR endocytotic pathway
(29).
The CendR pathway is most similar
to macropinocytosis; however, unlike
macropinocytosis, it is receptor dependent.
The required receptor is the neuropilin
receptor. Upon activation of the receptor, the
endocytic vesicles will form, which can
uptake any particle small enough into the cell
such as a nanoparticle (30). The nanoparticle
will then be released into the cytoplasm and
is free to undergo its own specific activity. In
this case, the activity would act as an
inhibitor of HIF-a, which would prevent its
translocation into the nucleus and prevent
activation of the HIF transcription factor.
Along with the upregulated
expression of the avb3 and avb5 integrins in
the tumor endothelial tissue, the neuropilin
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receptor is also overexpressed, leading to an
upregulated activation of the CendR pathway
(29). The receptor is upregulated due to the
fact that tumors are typically in a nutrient
deprived state. The enzyme mTOR acts a
senor for nutrients, and when it senses a
deprived state, it will signal for the
overexpression of neuropilin (29). Neuropilin
has been shown to be overexpressed in a
wide variety of tumors including: prostate,
breast, melanoma, pancreas and glioblastoma
cancers (28). One advantage to this specific
receptor is that it has not been shown to be
upregulated on endothelial cells in normal
vasculature. Due to this fact, peptides that
bind to the neuropilin receptors are termed
TTPs (28). Also, it has been found that drugs
that are conjugated with the iRGD peptide
have an increased accumulation in tumors by
4-5-fold. This was shown in mice models
with solid tumors (31).
Currently evidence is strongest for
the use of nanoparticles conjugated with the
iRGD peptide. However, it is believed that
liposomes may be able to be modified with
the iRGD peptide allowing for the activation
of this pathway. Liposomes are suitable for
nano drug delivery due to their controllable
size and their ability to be modified (28). The
issue that arises with the use of liposomes is
that they have been shown to not penetrate
deep into tumors as well as nanoparticles due
to the complexity of the highly dense ECM
and the rapidly increasing IFP in the center
and periphery of the tumor (28). Because of
this fact, it is proposed at the time to further
study the conjugate of a HIF-a inhibitor with
the iRGD peptide, which will avoid the
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obstacles that are present with the use of
liposomes.
Increased clinical efficacy of
radiotherapy can possibly be achieved with a
targeted release of an HIF-1a inhibitor (4).
By using a systemic chemotherapeutic such
as the one proposed in combination with
normal RT treatment could prevent the
adverse effects that are seen upon activation
of the hypoxia pathway due to RT treatment.
Using this approach would prevent the
formation of new vasculature within the solid
tumor and could possibly cause necrosis of
the tumor due to lack of access to adequate
nutrients and oxygen. With the hypoxia
pathway already inhibited, the tumor would
not be able to undergo angiogenesis and
could possibly prevent future metastasis from
occurring, which both have been shown to be
upregulated by HIF-1 formation.
Increased efficacy for cancer-type
specific chemotherapeutics would be
beneficial if there are CSCs present in the
solid tumor. CSCs are responsible for the
regrowth of new tumors and must be
eliminated to prevent future relapses (24).
Upon completion of a round of combined RT
with a specific HIF-1a inhibitor, the solid
tumor will have decreased blood flow,
decreasing the chances of the
chemotherapeutic from reaching the CSCs.
However, if there are CSCs present that are
radio-resistant, research has shown, the best
treatment option typically relies on the use of
present systemic chemotherapeutics (24).
Since there will be a decrease in the overall
mass of the solid tumor, the systemic
chemotherapeutics could possibly have a
better chance of targeting the CSCs, which
would lead to the increased efficacy. This is
outside the scope of this paper, but it may
benefit from future research upon successful
formulation of the combined RT, HIF-1a
treatment plan.
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Conclusion
Radiotherapeutics have been shown
to be an effective treatment option for a
variety of tumor types in controlling tumor
progression and may being curative under
certain circumstances. Although radiotherapy
is effective, it has been shown to cause
changes in the makeup of the tumor
microenvironment leading to cycles of
hypoxia. Although theses cycles have no
initial impact on the tumor, they may lead to
downstream effects such as angiogenesis,
tumor proliferation and tumor metastasis,
which are correlated with a worse prognosis.
These effects have been shown to be
correlated with the activation transcription
factor HIF-1 during a hypoxic state.
Activation of the transcription factor occurs
when HIF-1a subunits translocate from the
cytoplasm into the nucleus and bind with the
HIF-1b subunits and leads to an increase in
the expression of VEGF, PDGF, and TGF-a
along with a variety of other genes.
When angiogenesis occurs in the
tumor microenvironment, the vasculature is
disarrayed compared to that of normal
vasculature due to the overexpression of proangiogenic factors. The vasculature is leakier
leading to the accumulation of excessive
fluid and proteins inside the tumor. Also, as
the cells deep within the tumor are
proliferating, STP increases due to the
increase in cell density. Together, this leads
to an increase in the IFP which has been
shown to hinder the distribution of
chemotherapeutics deep in the tumor.
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Tumor targeting peptides, which
express a iRGD motif, selective for
endothelial cells within the tumor have
shown promising in mice models to increase
the accumulation of nanoparticles deep
within tumors upon activation of the CendR
pathway. A nanoparticle that can inhibit the
translocation of HIF-a subunits into the
nucleus that is conjugated with a iRGD motif
may prevent the accumulation of excess proangiogenic factors in the tumor
microenvironment post-treatment by
radiation. Therefore, this nanoparticle could
potentially increase the clinical efficacy of
radiotherapeutics and being selective to only
tumor tissue would decrease the risk of
additive toxicity.
Limitations
HIF-1 has been highly correlated with
the accumulation of pro-angiogenic factors;
however, they are not the only transcription
factors that can signal for their
overexpression. Therefore, although HIF-1
inhibition may successfully prevent
angiogenesis, cell growth/proliferation and
metastasis, there may be other pathways that
the cell could activate to accommodate the
revascularization of the tumor (9).
Future Research
This is a proposal of a new
conjugated nanoparticle that has yet to be
made or tested in a laboratory or clinical
setting. Thus, research needs to be completed
in the creation and efficacy of the proposed
selective chemotherapeutic and on how
specifically it is taken up by the tumor, how
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much it may decrease the accumulation of
pro-angiogenic factors and if the cancerous

cells will activate other pathways to
revascularize the tumor.
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Formatting of this paper was completed following the National Library of Medicine (NLM)
guidelines.
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